Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
AVAX Appoints Chief Medical Officer for EMEA
April 16th, 2008
AVAX Technologies, Inc. (OTC Market: AVXT.OB) announces the appointment of Isabelle Fourthin, MD as Chief Medical Officer for Europe, Middle East and Africa (EMEA). Dr. Fourthin will be responsible for recruiting and overseeing European clinical sites for AVAX's phase III registration study of MVax(R), its autologous, hapten-modified melanoma vaccine, and for new indications for the AC-Vaccine technology as they develop. Dr. Fourthin comes to AVAX with over thirteen years of experience in the pharmaceutical/biotech industry in Europe. Most recently she was Medical Director, Oncology with Merck & Co., Inc. based in Paris. Previously, she held a Chief Medical Officer...
Source: Vaccine Weekly (2008-04-16)
|
